key: cord-0950985-ziaiufzs
authors: Liu, Chang; Ginn, Helen M.; Dejnirattisai, Wanwisa; Supasa, Piyada; Wang, Beibei; Tuekprakhon, Aekkachai; Nutalai, Rungtiwa; Zhou, Daming; Mentzer, Alexander J.; Zhao, Yuguang; Duyvesteyn, Helen M.E.; López-Camacho, César; Slon-Campos, Jose; Walter, Thomas S.; Skelly, Donal; Johnson, Sile Ann; Ritter, Thomas G.; Mason, Chris; Costa Clemens, Sue Ann; Naveca, Felipe Gomes; Nascimento, Valdinete; Nascimento, Fernanda; Fernandes da Costa, Cristiano; Resende, Paola Cristina; Pauvolid-Correa, Alex; Siqueira, Marilda M.; Dold, Christina; Temperton, Nigel; Dong, Tao; Pollard, Andrew J.; Knight, Julian C.; Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij-Rammerstorfer, Sandra; Gilbert, Sarah C.; Malik, Tariq; Carroll, Miles W.; Klenerman, Paul; Barnes, Eleanor; Dunachie, Susanna J.; Baillie, Vicky; Serafin, Natali; Ditse, Zanele; Da Silva, Kelly; Paterson, Neil G.; Williams, Mark A.; Hall, David R.; Madhi, Shabir; Nunes, Marta C.; Goulder, Philip; Fry, Elizabeth E.; Mongkolsapaya, Juthathip; Ren, Jingshan; Stuart, David I.; Screaton, Gavin R.
title: Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
date: 2021-06-17
journal: Cell
DOI: 10.1016/j.cell.2021.06.020
sha: be782cbc92002247a1d7ab403e5db713927d1dcc
doc_id: 950985
cord_uid: ziaiufzs

SARS-CoV-2 has undergone progressive change with variants conferring advantage rapidly becoming dominant lineages e.g. B.1.617. With apparent increased transmissibility variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the UK. Here we study the ability of monoclonal antibodies, convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2 and complement this with structural analyses of Fab/RBD complexes and map the antigenic space of current variants. Neutralization of both viruses is reduced when compared with ancestral Wuhan related strains but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2 suggesting that individuals previously infected by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insight for immunisation policy with future variant vaccines in non-immune populations.

Reports of a severe acute respiratory syndrome in Wuhan China first appeared in December 2019. It was rapidly determined that coronavirus disease 2019 was caused by infection with a novel beta coronavirus related to the SARS coronavirus and named SARS-CoV-2 (Gorbalenya et al., 2020) . SARS-CoV-2 spread rapidly leading to the global pandemic which is still accelerating and has been estimated to have led to 164M infections and 3.4M deaths (https://www.worldometers.info/coronavirus Accessed: 2021-05-17).

Since the first sequence of SARS-CoV-2 was deposited in early January 2020 (Lu et al., 2020) , viral genome sequencing efforts have been established in a number of countries to track the evolution of the virus (COG- UK Consortium, 2020) . Coronaviruses are large J o u r n a l P r e -p r o o f positive strand RNA viruses and despite some proof-reading capacity (Robson et al., 2020) , replication is intrinsically error prone. Progressive mutational change in the virus is therefore inevitable as it undergoes massive numbers of replicative cycles worldwide (Tegally et al., 2021) . In particular, changes were anticipated as the virus adapts to its new human host.

Many thousands of mutational changes have been described across the viral genome and whilst most will be detrimental or confer no advantage to the virus, some will be advantageous and be the subject of rapid natural selection (Domingo et al., 2012; Rambaut et al., 2020) . Mutations could confer advantage to the virus in a number of ways, but increased transmissibility or escape from innate or acquired immune responses are two potential examples (Volz et al., 2021) .

Spike protein (S) is the major surface glycoprotein on coronaviruses. These characteristically trimeric spikes are subdivided into an N-terminal S1 domain responsible for attachment to host cells via its receptor ACE2 (Hoffmann et al., 2020 ) and a C-terminal S2 domain which is anchored in the viral membrane, cleaved from S1 following cellular attachment and responsible for membrane fusion and cell entry. S1 consists of an N-terminal domain (NTD) followed by the receptor binding domain (RBD) which mediates binding to ACE2, burying ~860 Å of surface area at its tip (Lan et al., 2020) .

Analysis of panels of monoclonal antibodies binding to S has led to the identification of a number of potently neutralizing antibodies, some of which have been developed for therapeutic and prophylactic use (Ku et al., 2021; Baum et al., 2020) . Antibodies to S2 tend to be poorly neutralizing while potently neutralizing antibodies generally map to S1. Most potent neutralizing antibodies bind the RBD, either on or closely adjacent to the ACE2 interacting J o u r n a l P r e -p r o o f surface and function to block interaction of the virus with ACE2, thereby preventing cellular adhesion and infection (Dejnirattisai et al., 2021; Yuan et al., 2020; Kreye et al., 2020) . A second class of potently neutralizing antibodies bind to a site on the NTD termed the supersite, these antibodies do not block interaction with ACE2 and their mode of neutralization is less well understood (Cerutti et al., 2021; Chi et al., 2020; Dejnirattisai et al., 2021) .

Many mutations in S have been reported and it appears that the RBD and especially NTD are mutational hotspots (Greaney et al., 2021) . The ACE2 interacting surface of S is under intense selective pressure as changes may increase ACE2/RBD affinity, potentially increasing virus transmissibility, whilst the same changes may also reduce antibody binding to the RBD, decreasing the neutralizing potential of immune serum. In late 2020 three variants of concern were identified, B.1.1.7 in the UK, B.1.351 in South Africa and P.1 in Brazil, which rapidly became the dominant variants locally, leading to large second waves of infection and they continue to spread globally. These variants contain changes in the RBD; B.1.1.7 N501Y; B.1.351 N501Y, E484K, K417N and P.1 N501Y, E484K and K417T. These changes increase the affinity of ACE2 to RBD 7-fold for B.1.1.7 and 19-fold for B.1.351 and P.1, which may play a role in increased transmissibility. The neutralizing titres of convalescent and vaccine serum are reduced to the variants with B.1.351 of most concern, leading to a 13-fold reduction in neutralizing titres of convalescent serum with a number of neutralizing monoclonal antibodies completely losing activity Supasa et al., 2021; Dejnirattisai et al., 2021b; Shinde et al., 2021; Madhi et al., 202; Vaccines and Related Biological Products Advisory Committee, 2021; Emary et al., 2021) .

There are now at least 15 vaccines authorised for use in one or more countries, and these are designed to elicit antibody (and T-cell) responses to S using S sequences from the original Wuhan virus deposited in January 2020. Vaccines deliver S in a variety of different formats;

RNA, viral vectors, recombinant protein or inactivated virus (Krammer, 2020; Polack et al., 2020; Voysey et al., 2020; Baden et al., 2020) (https://www.medscape.com/viewarticle/944933 Accessed: 2021-03-01). Since the S sequence of variant viruses differ from that used for vaccination there is concern that variant viruses may have the potential to evade antibody responses elicited by vaccination. Several studies have now shown that there is reduced vaccine efficacy against mild to moderate disease in countries where B1.351 was dominant Shinde et al., 2021; Madhi et al., 2021, Vaccines and Related Biological Products Advisory Committee, 2021) , though protection against severe disease appears to be preserved. Conversely, vaccine efficacy against B.1.1.7 is maintained (Wang et al., 2021; Emary et al., 2021; Supasa et al., 2021) .

In this paper we study two variant viruses B.1.617.1 (bearing mutations L452R and E484Q in the RBD) and B.1.617.2 (bearing RBD mutations L452R and T478K) which were first reported from India at the end of 2020 but have spread globally (https://www.gisaid.org/hcov19-variants/) with B.1.617.2 causing particular concern in the UK where it is spreading rapidly and was designated a variant of concern in May 2021. Using a panel of potent neutralizing antibodies, we show that both viruses show partial or complete escape from neutralization by some antibodies but that neutralization of most monoclonal antibodies is unaffected. Neutralization by a panel of plasma collected from convalescent cases from the UK early in the pandemic show 4-fold and 2.7-fold reduction in neutralization titres to B.1.617.1 and B.1.617.2 respectively, compared to an early Wuhan related strain.

There are also significant reductions in neutralization titres of sera collected from recipients of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines but no evidence of widespread complete escape from neutralization. We also look at the ability of sera from individuals infected with B. in affinity compared to the Wuhan RBD sequence, use structural information to identify the mechanism of escape from monoclonal antibodies and perform a simple analysis of antigenic distances between variants to illustrate the emerging antigenic landscape of SARS-CoV-2.

The B. have become the second and third-most widespread variants of concern respectively according to COG-UK data (COG-UK, Consortium, 2020) ( Figure 1A) (which may increase furin cleavage of S1), the S2 mutation Q1071H and up to three NTD substitutions: T95I, G142D and E154K ( Figure 1B ). E484Q is a mutation at the same position as E484K seen in the B.1.351 and P.1 variants, although the change in physicochemical properties is less for the glutamine than the lysine sidechain Dejnirattisai et al., 2021b) . B.1.617.2 ( Figure 1C) A number of potent monoclonal antibodies are being developed for clinical use and some have received emergency use authorisation (Ku et al., 2021; Baum et al., 2020; Kemp et al., 2021) . We performed neutralization assays against B.1.617.1 and B.1.617.2 using antibodies S309 Vir (Pinto et al., 2020) , AZD8895, AZD1061 and the combination AZD7442

AstraZeneca, REGN10987 and REGN10933 Regeneron, LY-CoV555 and LY-CoV16 Lilly and ADG10, ADG20 and ADG30 from Adagio ( Figure 2B , Figure 3B ,C). It will be seen, as expected, that the antibodies affected are proximal to the mutation sites. The antibodies most affected are especially in the top and front in the neck epitope (nomenclature of (Dejnirattisai et al., 2021a) ), with a small impact on some antibodies belonging to the right flank epitope. The reasoning presented above for the assignment of individual mutations to effects on antibody potency is consistent with the site of antibody attachment.

We performed three exemplar structural analyses to test our understanding of the physicochemical basis of antibody escape. Firstly, we determined the crystal structure (at 2.3 Å resolution) of Fab 278 in complex with Victoria RBD and Fab 222 (Methods, Figure 4A - Figure 3B ) (Dejnirattisai et al., 2021a) , suggesting that such antibodies are not uncommon in responses to infection with Victoria-like viruses.

Secondly, we determined the crystal structure of a ternary complex of RBD-L452R with Fabs 253 and 75 (Methods, Figure 4G and Table S1 ). The RBD 452 mutation had no effect on neutralization or binding of mAb 253 and the structure confirms that the RBD L452R mutation introduces no significant change in the RBD structure and residue 452 does not directly contact Fab 253 ( Figure 4G ). The third crystal structure determined is closely related, it is a ternary complex of Fab 253 with RBD-T478K and Fab 45 ( Figure 4H , Table   S2 ). Fab 253 is the only antibody whose binding is significantly perturbed by the mutation at RBD residue 478 (the closely related mAb 55 shows a similar but reduced effect) and the mutation to lysine actually increases neutralisation titre by approximately one log. Perhaps surprisingly this is the only example we have come across of a marked increase in binding to J o u r n a l P r e -p r o o f a variant virus and the structure confirms that this effect is due to direct interaction with RBD residue 478, with the lysine side chain in the variant RBD folding away behind the CDR1 loop of the LC (Figure 4I ,J). In addition, comparison of the overall mode of engagement of mAb 253 between the two differently mutated RBDs reveals that the 478 mutation induces a modest change in the pose of the antibody ( Figure 4I ). It is perhaps surprising that the threonine to lysine mutation of RBD residue 478, which represents a marked change in size and charge has no deleterious effect on the binding of any of our set of potent monoclonal

antibodies. This suggests that antibody response against Victoria-like viruses do not include a significant number of potent neutralising antibodies that bind in this region, perhaps because this residue is towards the back of the left shoulder facing away from the area where ACE2

attaches. Nevertheless, this residue is extremely exposed and it is possible that responses in people infected by B. Figure 1B) .

We collected 4-9 week convalescent plasma from individuals infected during the first wave of infection in the UK before June 2020, plasma from individuals infected with B.1.1.7 in the UK (n=18) confirmed by sequence or S-gene knock out in diagnostic PCR), serum from cases of P.1 (n=17 sequence confirmed) collected in Brazil and serum from cases of B.1.351 collected from the UK and South Africa (n=14) sequence confirmed n=12, or isolated contacts of sequence confirmed cases who developed infection during quarantine n=2) (Dejnirattisai et al., 2021a; Supasa et al., 2021; Zhou et al., 2021; Dejnirattisai et al., 2021b) .

Neutralization of B.1.617.1 pseudoviruses were compared to neutralization of Victoria using the UK samples taken in early 2020 ( Figure 5A ,B, Figure 6B -D).

Serum from donors infected with B.1.1.7 appears to give good protection against all variants of concern whereas, protection from B. 

AstraZeneca vaccine (Polack et al., 2020; Voysey et al., 2020) . For Pfizer-BioNTech, serum was collected 4-14 days following the second dose of vaccine administered 3 weeks after the first dose (n=25). For the Oxford-AstraZeneca vaccine, serum was taken 14 or 28 days following the second dose, administered 8-14 weeks following the first dose (N=25).

Geometric mean neutralization titres against B.1.617.1 were reduced 2.7-fold (p<0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum ( Figure 7A , Figure S5 , Table S3 ) and 2.6-fold (p<0.0001) for the Oxford-AstraZeneca vaccine ( Figure 7B ). For B.1.617.2 titres were reduced 2.5-fold (p<0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum ( Figure 7C ) and 4.3-fold (p<0.0001) for the Oxford-AstraZeneca vaccine ( Figure 7D ). For B.1.617.2 reductions were comparable to those seen with B.1.1.7

and P.1 (Supasa et al., 2021; Dejnirattisai et al., 2021b) with only a small number of samples failing to reach FRNT50 titres at 1:20 serum dilution in contrast to the results seen for neutralization of B.1.351 ( Figure S4 ).

Finally, we performed neutralization assays using sera from volunteers 4 (n=20) and 10 weeks 

The antigenic landscape of the present major variants

To visualise and quantify the emerging antigenic landscape of SARS-CoV-2 we devised a method related to antigenic cartography (Smith et al., 2004; Fonville et al., 2014) . We define 'antigenic distance' by comparison of the log of dilution values for 50% neutralisation for all the available serum/virus strain pairs (Dejnirattisai et al., 2021a; Supasa et al., 2021; Dejnirattisai et al., 2021b) . Three principal axes of variation determined by single value decomposition of this serum/virus strain matrix were displayed to show the distribution of the strains in antigenic space. The result, using the somewhat incomplete set of data available from our studies is shown in (Figure 7I , Supplementary Video 1). This provides a very simple view onto complex, sparse and noisy data and confirms the inferences made above, that the largest distance is between the B. 

The inevitable evolution of SARS-CoV-2 following its zoonotic transfer to humans in Wuhan in late 2019 prompted the establishment of sequencing efforts such as COVID-19 genomics UK (COG-UK) (COG-UK Consortium, 2020). SARS-CoV-2 genome surveillance in many parts of the world was slow to start and there are many regions where surveillance is either absent or completely underpowered compared with the scale of infections. It is likely that the true scale of the diversity in SARS-CoV-2 is underestimated and that further concerning variants are circulating and will continue to arise. Early in the pandemic SARS-CoV-2 was under selective pressure to adapt to its new host, to evade the innate immune system, to J o u r n a l P r e -p r o o f efficiently bind to and infect target cells and to transmit to the next host. As the population develops immunity, by either natural infection or vaccination, pressure is mounting to select mutations that allow the virus to more effectively find an infectible host through increased transmissibility, or to evade the acquired immune response and cause reinfection.

Since the S protein is intimately involved in the initiation of infection and is the target of neutralizing antibody responses it is no surprise that it is evolving rapidly and that changes in S likely underpin some of the phenotypes expressed by variants of concern. S is a large protein >1200 amino acids but a very small 25 amino acid patch at its apex, mediating RBD/ACE2 interaction, is key. Mutations in and around the ACE2 interacting surface are found in all the variants of concern B.1.1.7, B.1.351, P.1 as well as the three B.1.617 sublineages ( Figure 7H ).

In this report we have measured the affinities for B. evolution experiments demonstrated that the increases in RBD/ACE2 affinity seen in today's variants of concern are far from the limits that can be achieved, so in the future more radical J o u r n a l P r e -p r o o f antigenic variation, which would render the virus unfit by reducing affinity for ACE2 might be rescued by employing these ACE2-binding enhancing mutations.

A hotspot for S sequence change is the NTD with multiple changes occurring in tandem consisting of amino acid substitutions together with small deletions and insertions. The NTD is the site of binding of a number of potently neutralizing antibodies whose mode of action is not yet fully understood since unlike most potent anti-RBD antibodies they do not block immunization of those at highest risk (older adults and those with co-morbidities) globally with at least one dose of the current generation of vaccines is urgently needed. It is known that the proportion of the population with strong neutralizing activity increases with a second dose and we find that following a single dose of Pfizer-BioNTech vaccine neutralisation neutralization of B.1.617.2 is limited. Administration of two doses for those at greatest risk will therefore be needed to prevent infection. Of interest, infection with B.1.1.7 seems to provide reasonable cross-protection against all variants of concern, which means B.1.1.7 might be a candidate for new variant vaccines to provide the broadest protection.

Of more concern, was the neutralization of B. and robust serological data such as those presented here are obtained then it becomes essential to visualise and quantify the antigenic landscape of SARS-CoV-2 rather than rely on such.

increasingly complicated, narrative explanations. We present such a method ( Figure 7J , Video S1), related to those termed antigenic cartography. We define a multidimensional antigenic space representing 'antigenic distances' within the sero-complex and show that even using the incomplete data available projecting the principle components into to a lowerdimensional space allows visualisation of the antigenic relationships between the different lineages, confirming the qualitative assessment that the largest distance is between B. boosting will be to redirect the response towards the variants from the initial prime with Wuhan is to be determined. However, it is becoming more likely that more than one variant will be required to provide protection as the SARS-CoV-2 sero-complex continues to evolve, we suggest that one component will likely continue to include Wuhan related strains or B.1.1.7 as, for now at least, they appear to be more centrally positioned in the sero-complex, able to provide protection against multiple viral variants.

Finally, we show a 1.34-fold reduction between 4 and 10 weeks in neutralization titres to In summary, we report an in-depth study of antibody binding and neutralization of B.1.617.1 and B.1.617.2 viruses. Although there is reduction in neutralization titres using convalescent or vaccine sera there is no evidence of widespread escape suggesting that the current generation of vaccines will provide protection against the B.1.617 lineage, although reduced titres may lead to some breakthrough infections. However, there is a concern that some unvaccinated individuals previously infected with B.1.351 and P.1 may be more at risk of reinfection with B.1.617.2. Further epidemiological data are needed to assess whether breakthrough infections following escape mutations are common, and whether they will progress to severe disease and hospitalisation. If this escape from the neutralising capacity of vaccines continues with evolution of new variants in vaccinated populations, and leads to a substantial reduction in effectiveness against hospitalisation, there will be a significant impact on attempts to alter the course of the pandemic through immunisation and an urgent need to revise immunogens.

We have compared pseudoviral neutralization data with live virus data, which is not ideal as some pseudoviral constructs did not recapitulate neutralization live virus assays for monoclonal antibodies and we believe that live virus assays are preferable when available.

The in vitro neutralization assays described here are performed in the absence of complement for Victoria that we have previously generated (Supasa et al., 2021) . Neutralization titres are reported in Table S1 . (B) Shows equivalent plots for the Vir, Regeneron, AstraZeneca, Lilly and Adagio antibodies. Experimental data for the dilution series are shown in different colors and the models as red lines. (B) Neutralisation data (NT50) and BLI data (K D ) mapped onto the RBD using the J o u r n a l P r e -p r o o f method described (Dejnirattisai et al., 2021 

Resources, reagents and further information requirement should be forwarded to and will be responded by the Lead Contact, David I Stuart (dave@strubi.ox.ac.uk).

Reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

The coordinates and structure factors of the crystallographic complexes are available from the PDB with accession codes: 7OR9, 7ORA, 7ORB (see Table S1 ). Mabscape is available from https://github.com/helenginn/mabscape, https://snapcraft.io/mabscape. The data that support the findings of this study are available from the corresponding authors on request.

SARS-CoV-2/human/AUS/VIC01/2020 , SARS-CoV-2/B. Data from vaccinated volunteers who received two vaccinations are included in this paper.

Vaccine doses were either 5 × 10 10 viral particles (standard dose; SD/SD cohort n=21) or half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort J o u r n a l P r e -p r o o f n=4). The interval between first and second dose was in the range of 8-14 weeks. Blood samples were collected and serum separated on the day of vaccination and on pre-specified days after vaccination e.g. 14 and 28 days after boost.

The neutralization potential of Ab was measured using a Focus Reduction Neutralization Test (FRNT), where the reduction in the number of the infected foci is compared to a negative control well without antibody. Briefly, serially diluted Ab or plasma was mixed with SARS-CoV-2 strain Victoria or P.1 and incubated for 1 hr at 37 °C. The mixtures were then transferred to 96-well, cell culture-treated, flat-bottom microplates containing confluent Vero cell monolayers in duplicate and incubated for a further 2 hrs followed by the addition of 1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit virus diffusion. A focus forming assay was then performed by staining Vero cells with human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human IgG (A0170;

Sigma). Finally, the foci (infected cells) approximately 100 per well in the absence of antibodies, were visualized by adding TrueBlue Peroxidase Substrate. Virus-infected cell foci were counted on the classic AID EliSpot reader using AID ELISpot software. The percentage of focus reduction was calculated and IC 50 was determined using the probit program from the SPSS package.

The constructs of pseudotyped lentivirus expressing SARS-CoV-2 S proteins are as previously described in Nie et al. (Nie et al., 2020) , with some modifications. Briefly, the gene sequences were designed to encode S protein of Victoria (S247R), B. . A synthetic codon-optimised SARS-CoV-2 construct from Wuhan-Hu-1 (GenBank:

MN908947) was used as the template and the constructs were cloned by PCR amplification of vector and inserts, followed by Gibson assembly. To generate the insert fragments, the overlapping primers for all individual variants were used separately to amplify, together with two primers of pcDNA3.1 vector (pcDNA3.1_BamHI_F and pcDNA3.1_Tag_S_EcoRI_R).

The pcDNA3.1 vector was also amplified using pcDNA3.1_Tag_S_EcoRI_F and pcDNA3.1_BamHI_R primers. The primer pairs used in this study are shown in supplementary ( Table S5) . All constructs were verified by Sanger sequencing.

Production of pseudotyped lentiviral particles expressing SARS-CoV-2 S protein was carried A similar strategy was used to produce lentiviral vector carrying human ACE2 (hACE2).

However, the plasmid expressing SARS-CoV-2 S and luciferase reporter proteins were replaced by the Vesicular stomatitis virus G protein (pCMV-VSV-G) and vector expressing human ACE2 (pHR-SIN-ACE2). Both plasmids were kindly provided by Alain Townsend.

The resulting lentiviral particles were transduced into HEK293T/17 cells to generate the stable expressing hACE2 receptor. The transduced cells were subjected to hACE2 staining and single cell sorting, clones with >80% hACE2 positive cells were used as the target cells for pseudotyped based neutralization assays. were then added to the mixture at 1.5x10 4 cells/well. Plates were spun at 500 RCF for 1 min and further incubated for another 48 hr. Culture supernatants were removed and 50 µL of 1:2

Bright-GloTM Luciferase assay system (Promega, USA) in 1X PBS (sigma) was added to each well. The reaction was incubated at room temperature for 5 mins and the firefly luciferase activity was measured using CLARIOstar® (BMG Labtech). The percentage of J o u r n a l P r e -p r o o f neutralization of mAbs or plasma samples towards pseudotyped lentiviruses was calculated relative to the control.

The constructs of ACE2, WT RBD, B.1.1.7, B.1.351 and P.1 mutant RBD are the same as previously described (Dejnirattisai et al. 2021 , Supasa et al., 2021 . To clone RBD expression plasmids which has the same nucleotide optimization with the spike of pseudovirus (RBD-PV), the sRBD fragment were amplified from pcDNA 3.1-SARS-CoV-2

Spike plasmids using primers of PV-RBD. pNEO vector was digested by AgeI and KpnI and joined with RBD fragments by Gibson assembly.

To construct RBD L452R and T478K, primers of L452R and primers of T478K were used separately, together with two primers of pNEO vector to do PCR, with the plasmid of RBD-PV as the template. To construct RBD L452R T478K and RBD L452R E484Q, primers of T478K and RBD E484Q were used to pair with the primers of pNEO vector to do PCR, with the plasmid of RBD L452R as template. Two PCR fragments amplified for each mutation were purified by QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) and used as templates to be joined together by further PCR with the two primers of pNEO vector.

Amplified DNA fragments were digested with restriction enzymes AgeI and KpnI and then ligated into digested pNEO vector. All constructs were verified by sequencing.

Protein production was as described in Zhou et al. (Zhou et al., 2020) . 

BLI experiments were run on an Octet Red 96e machine (Fortebio). To measure the binding affinity of ACE2 with different RBD variants, each RBD was immobilized onto AR2G biosensors (Fortebio) and serial dilutions of ACE2 were used as analytes. To measure the binding affinity of monoclonal antibodies with RBD variants, each his-tagged RBD was immobilized onto Ni-NTA biosensors (Fortebio) and antibodies (Dejnirattisai et al., 2021a) were used as analytes All experiments were run at 30 °C. Data were recorded using software Data Acquisition 11.1 (Fortebio) and Data Analysis HT 11.1 (Fortebio) with a 1:1 fitting model used for the analysis. Table S2 . Structural comparisons used SHP (Stuart et al., 1979) , residues forming the RBD/Fab interface were identified with PISA (Krissinel and Henrick, 2007) and figures were prepared with PyMOL (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC).

Log of IC 50 values for each serum/virus strain pair were assembled into vectors for each virus strain. 113 sera from a range of natural infections and vaccinations were used in total and compared against 7 virus strains, assembling a 113x7 matrix. Single value decomposition of this serum/virus strain pair matrix was carried out, producing weighted orthogonal vectors representing the axes of variation within the data and each strain was expressed as a vector in this new orthogonal basis. The largest axis of variation was largely identical for each strain, representing the positivity in common with all log dilution values. The 2nd, 3rd and 4th major axes were plotted using cluster4x (Ginn, 2020) Table S2 . Table S3 . Table S3 . Table S4 . Table S4 .

Video S1. 3D view of antigenic space plot for current variants, related to Fig. 7I .

J o u r n a l P r e -p r o o f Table S3 . NT50 titres against pseudo typed lentiviruses expressing full-length spike of SARS-CoV-2 strains Victoria and B.1.617.1, and live virus strains Victoria and B.1.617.2 (A) 34 convalescent plasma during early pandemic in UK (B) plasma from 18 patients infected with B.1.1.7 (C) serum from 14 patients infected with B.1.351 (D) serum from 17 patients infected with P.1 . The data underpinning the Victoria live virus neutralization curves of convalescent samples have been previously reported (Supasa et al, 2021) . Related to Figure5 and 6.

An integrated national scale SARS-CoV-2 genomic surveillance network

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Viral Quasispecies Evolution. Microbiol

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Coot: Model-building tools for molecular graphics

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Antibody landscapes after influenza virus infection or vaccination

Production, titration, neutralisation and storage of SARS-CoV-2 lentiviral pseudotypes

Pre-clustering data sets using cluster 4 x improves the signal-to-noise ratio of high-throughput crystallography drug-screening analysis

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 evolution during treatment of chronic infection

SARS-CoV-2 vaccines in development

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Inference of Macromolecular Assemblies from Crystalline State

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Covid-19 Vaccine against the B.1.351 Variant

Phaser crystallographic software

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

Tracking the COVID-19 pandemic in Australia using genomics

Efficacy of NVX

Vaccine against the B.1.351 Variant

Natural and vaccine-induced antibody and cellular responses against emerging SARS-CoV-2 variants of concern, PREPRINT (Version 1) available at Research Square

Mapping the antigenic and genetic evolution of influenza virus

Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 Å

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Sixteen novel lineages of SARS-CoV-2 in South Africa

The use of retroviral pseudotypes for the measurement of antibody responses to SARS coronavirus

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

A procedure for setting up high-throughput nanolitre crystallization experiments. I. Protocol design and validation

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Xia2: An expert system for macromolecular crystallography data reduction

DIALS : implementation and evaluation of a new integration package

Structural basis of a shared antibody response to SARS-CoV-2

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera

• Vaccine/convalescent sera show reduced neutralization of B.1.617.1 and B.1

• Sera from B.1.351and P.1 show markedly reduced neutralization of B.1

This work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation